The Absorb GT1 Bioresorbable Vascular Scaffold System ― 5-Year Post-Market Surveillance Study in Japan ―
Circulation Journal · 24.05.2024 · 88 (6) · 863-872
DOI: 10.1253/circj.cj-23-0877 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Circulation Journal, erschienen am 24.05.2024. Verfasst von Masato Nakamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center. Hauptthemen laut MEDLINE: Absorbable Implants, Product Surveillance, Postmarketing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The 1-year clinical outcomes of the Absorb GT1 Japan post-market surveillance (PMS) suggested that an appropriate intracoronary imaging-guided bioresorbable vascular scaffold (BVS) implantation technique may reduce the risk of target lesion failure (TLF) and scaffold thrombosis (ST) associated with the Absorb GT1 BVS. The long-term outcomes through 5 years are now available. METHODS AND RESULTS: This study enrolled 135 consecutive patients (n=139 lesions) with ischemic heart disease in whom percutaneous coronary intervention (PCI) with the Absorb GT1 BVS was attempted. Adequate lesion preparation, imaging-guided appropriate sizing, and high-pressure post-dilatation using a non-compliant balloon were strongly encouraged. All patients had at least 1 Absorb GT1 successfully implanted at the index procedure. Intracoronary imaging was performed in all patients (optical coherence tomography: 127/139 [91.4%] lesions) and adherence to the implantation technique recommendations was excellent: predilatation, 100% (139/139) lesions; post-dilatation, 98.6% (137/139) lesions; mean (±SD) post-dilatation pressure, 18.8±3.5 atm. At 5 years, the follow-up rate was 87.4% (118/135). No definite/probable ST was reported through 5 years. The cumulative TLF rate was 5.1% (6/118), including 2 cardiac deaths, 1 target vessel-attributable myocardial infarction, and 3 ischemia-driven target lesion revascularizations. CONCLUSIONS: Appropriate intracoronary imaging-guided BVS implantation, including the proactive use of pre- and post-balloon dilatation during implantation may be beneficial, reducing the risk of TLF and ST through 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center.
- Fourth Department of Internal Medicine, Teikyo University School of Medicine.
- Department of Cardiovascular Medicine, Sakurabashi Watanabe Hospital.
- Department of Cardiovascular Medicine, Hanaoka Seishu Memorial Hospital.
- Department of Cardiovascular Medicine, Shin Koga Hospital.
- Department of Cardiovascular Medicine, Iwate Medical University Hospital.
Zitieren
APA
Nakamura, M., Suzuki, N., Fujii, K., Furuya, J., Kawasaki, T., Kimura, T., Sakamoto, T., Tanabe, K., Kusano, H., Stockelman, K. A., & Kozuma, K. (2024). The Absorb GT1 Bioresorbable Vascular Scaffold System ― 5-Year Post-Market Surveillance Study in Japan ―. Circulation Journal, 88(6), 863-872. https://doi.org/10.1253/circj.cj-23-0877
Vancouver
Nakamura M, Suzuki N, Fujii K, Furuya J, Kawasaki T, Kimura T, et al. The Absorb GT1 Bioresorbable Vascular Scaffold System ― 5-Year Post-Market Surveillance Study in Japan ―. Circulation Journal. 2024;88(6):863-872. doi:10.1253/circj.cj-23-0877
BibTeX
@article{Nakamura2024,
author = {Nakamura, Masato and Suzuki, Nobuaki and Fujii, Kenshi and Furuya, Jungo and Kawasaki, Tomohiro and Kimura, Takumi and Sakamoto, Tomohiro and Tanabe, Kengo and Kusano, Hajime and Stockelman, Kelly A and Kozuma, Ken},
title = {The Absorb GT1 Bioresorbable Vascular Scaffold System ― 5-Year Post-Market Surveillance Study in Japan ―},
journal = {Circulation Journal},
year = {2024},
volume = {88},
number = {6},
pages = {863--872},
doi = {10.1253/circj.cj-23-0877}
}
EUVIMED